Royalty Pharma plc (RPRX)
NASDAQ: RPRX · Real-Time Price · USD
58.10
+0.13 (0.22%)
Aug 11, 2026, 10:52 AM EDT - Market open

Royalty Pharma Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
2,5362,3782,2642,3552,2372,289
Revenue Growth
10.01%5.06%-3.86%5.24%-2.28%7.87%
Gross Profit
2,4302,6741,5311,7941,3331,837
Operating Income
1,5121,5601,2921,492307.071,431
Net Income
815770.95858.981,13542.83619.73
Earnings Per Share
1.881.781.912.530.101.49
EPS Growth
-18.26%-6.81%-24.51%2430.00%-93.29%12.88%

Revenue by Segment

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cystic Fibrosis Franchise
855.89828.18826.21852.31808.95762.89
Evrysdi
221.14206.97224.4397.74--
Trelegy
160.44154.1146.92128.0557.93-
Tremfya
191.36152.94147.14149.72109.816.71
Voranigo
172.98154.4246.15---
Tysabri
111.38116.88124.82167.54207.16211.42
Other Products
691.07647.67633.76629.24630.33507.52
Other Royalty Income and
131.74117.04114.15156.8112.12224.38
Revenue (Total)
2,5362,3782,2642,3552,2372,289

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
811.99618.7929.03477.011,7352,123
Total Debt
8,9628,9517,6126,1357,1167,096
Net Cash (Debt)
-8,150-8,332-6,683-5,658-5,381-4,973
Net Cash Growth
------
Net Cash Per Share
-14.62-14.76-11.25-9.39-12.29-11.99

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
2,9762,4902,7692,9882,1442,018
Free Cash Flow
2,9762,4902,7692,9882,1442,018
Free Cash Flow Growth
23.70%-10.08%-7.32%39.36%6.27%-0.84%

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
95.82%112.44%67.64%76.19%59.58%80.22%
Operating Margin
59.61%65.58%57.10%63.37%13.73%62.49%
Pretax Margin
53.23%55.68%58.79%72.20%10.28%54.21%
Profit Margin
53.23%55.68%58.79%72.20%10.28%54.21%
FCF Margin
117.37%104.69%122.33%126.89%95.83%88.12%

Dividends

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Dividend Per Share
0.9400.8800.8400.8000.7600.680
Dividend Per Share Growth
6.32%4.76%5.00%5.26%11.77%126.67%
Dividend Yield
1.62%2.28%3.29%2.85%1.93%1.73%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
31.2021.7113.3611.10395.2026.75
Forward PE
10.797.706.107.4710.3213.00
P/FCF Ratio
11.206.654.114.208.178.55
PS Ratio
13.146.965.035.337.837.54